CLINICAL TRIALS PROFILE FOR IMURAN
✉ Email this page to a colleague
All Clinical Trials for Imuran
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001789 ↗ | BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | 1999-06-01 | The purpose of this study is to investigate whether the experimental drug BG9588 can be used to treat lupus nephritis more effectively and with less toxicity than standard treatments, including cyclophosphamide (Cytoxan), azothioprine (Imuran) and prednisone. The body's immune system naturally produces antibodies to fight foreign substances like bacteria and viruses. In autoimmune diseases like lupus, however, the body makes antibodies that attack its own tissues, causing inflammation and organ damage. Lupus antibodies attack and damage kidney cells. BG9588 can interfere with the production of these antibodies, and therefore, may lessen kidney damage in people with lupus nephritis. This study will look at: how BG9588 enters and leaves the blood and body tissue over time; adverse effects of the drug; and whether treatment with BG9588 can result in less kidney damage than other therapies. Study patients will be receive a 30-minute infusion of BG9588 into a vein every two weeks for three doses and then once every 28 days for four doses. Patients' steroid dosage may be tapered; individual adjustments will be made as required. Patients screened for the study will undergo a physical examination, medical history, various blood and urine tests, as well as complete a quality of life questionnaire. Results of a previous kidney biopsy and chest X ray are also required. Many of these tests will be repeated throughout the study. In a previous animal study, BG9588 treatment of mice with lupus nephritis improved their disease and survival. |
| NCT00098111 ↗ | Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease | Terminated | Massachusetts General Hospital | Phase 3 | 2005-04-01 | The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects. |
| NCT00104299 ↗ | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | Completed | Genentech, Inc. | Phase 2/Phase 3 | 2005-01-01 | Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6. |
| NCT00104299 ↗ | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | Completed | Immune Tolerance Network (ITN) | Phase 2/Phase 3 | 2005-01-01 | Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6. |
| NCT00104299 ↗ | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2/Phase 3 | 2005-01-01 | Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6. |
| NCT00113503 ↗ | Imuran Dosing in Crohn's Disease Study | Terminated | Prometheus Laboratories | Phase 2 | 2005-07-01 | This study will compare two different dosing methods of azathioprine (IMURAN) in participants with Crohn's disease who are currently taking steroids (e.g. prednisone or budesonide)or who have just started steroids. The study can be up to 54 weeks long. All participants enrolled will receive active drug. Participants will take doses either based upon weight or based on the patient's ability to breakdown the drug (monitored by 6-thioguanine nucleotides (6-TGN) metabolite levels in the blood). All patients enrolled in the study will receive active study drug. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Imuran
Condition Name
Clinical Trial Locations for Imuran
Trials by Country
Clinical Trial Progress for Imuran
Clinical Trial Phase
Clinical Trial Sponsors for Imuran
Sponsor Name
| Sponsor Name for Imuran | |
| Sponsor | Trials |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| GlaxoSmithKline | 2 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2 |
| [disabled in preview] | 6 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
